{"transactions":[{"id":959161,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-12-29T21:23:31.000Z","date":"2025-12-23","kind":"purchase","planned":false,"acquired":true,"shares":8400,"price":1.6703,"value":14030.52,"ownership":{"direct":true},"balance_after":23179,"source":{"system":"sec-edgar","filing":"0000905148-25-004488","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825004488/form4.xml","form_type":"4"}},{"id":1007690,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-11-05T21:18:01.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-003785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003785/form4.xml","form_type":"4"}},{"id":1007688,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-11-05T21:17:44.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-003784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003784/form4.xml","form_type":"4"}},{"id":1007689,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-11-05T21:17:07.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-003783","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003783/form4.xml","form_type":"4"}},{"id":1007687,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-11-05T21:16:56.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":67492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Underlying shares each vested on November 3, 2025."}],"balance_after":67492,"derivative":{"exercise_price":1.15,"exercise_date":"2025-11-03","expiration_date":"2035-11-03","underlying":"Common Stock","underlying_shares":67492},"source":{"system":"sec-edgar","filing":"0000905148-25-003782","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003782/form4.xml","form_type":"4"}},{"id":1172356,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-04-15T11:59:38.000Z","date":"2025-04-14","kind":"purchase","planned":false,"acquired":true,"shares":325,"price":1.0018,"value":325.585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $0.99 through $1.05, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth."}],"balance_after":14779,"source":{"system":"sec-edgar","filing":"0000905148-25-001216","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001216/form4.xml","form_type":"4"}},{"id":1172353,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-15T11:59:22.000Z","date":"2025-04-14","kind":"purchase","planned":false,"acquired":true,"shares":490,"price":0.9985,"value":489.265,"ownership":{"direct":true},"balance_after":73639,"source":{"system":"sec-edgar","filing":"0000905148-25-001215","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001215/form4.xml","form_type":"4"}},{"id":1174489,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:29:49.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":1167,"price":0.8572,"value":1000.3524,"ownership":{"direct":true},"balance_after":73149,"source":{"system":"sec-edgar","filing":"0000905148-25-001190","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001190/form4.xml","form_type":"4"}},{"id":1174488,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-10T20:29:49.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":1136,"price":0.8747,"value":993.6592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $0.8741 through $0.88, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth."}],"balance_after":71982,"source":{"system":"sec-edgar","filing":"0000905148-25-001190","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825001190/form4.xml","form_type":"4"}},{"id":1258183,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:08:04.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-000740","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000740/form4.xml","form_type":"4"}},{"id":1258182,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T02:08:04.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60516,"source":{"system":"sec-edgar","filing":"0000905148-25-000740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000740/form4.xml","form_type":"4"}},{"id":1258180,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:48.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-000739","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000739/form4.xml","form_type":"4"}},{"id":1258179,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T02:07:48.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8500,"source":{"system":"sec-edgar","filing":"0000905148-25-000739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000739/form4.xml","form_type":"4"}},{"id":1258170,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:32.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-000738","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000738/form4.xml","form_type":"4"}},{"id":1258169,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T02:07:32.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14454,"source":{"system":"sec-edgar","filing":"0000905148-25-000738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000738/form4.xml","form_type":"4"}},{"id":1258178,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. On February 18, 2025, the reporting person received 1,733 shares of common stock of the issuer in settlement of RSUs, which vested on March 23, 2024."}],"balance_after":1733,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1733},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258177,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 770 shares of common stock of the issuer in settlement of RSUs, which vested on September 29, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":770},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258176,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":2311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 2,311 shares of common stock of the issuer in settlement of RSUs, which vested on July 1, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2311},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258175,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":3467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 3,467 shares of common stock of the issuer in settlement of PSUs."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3467},"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258174,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70846,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258173,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":770,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":69113,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258172,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":2311,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68343,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1258171,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-21T02:07:16.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":3467,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":66032,"source":{"system":"sec-edgar","filing":"0000905148-25-000737","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000737/form4.xml","form_type":"4"}},{"id":1423925,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-26T21:40:29.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":4094,"price":1.734,"value":7098.996,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.69 through $1.75, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth."}],"balance_after":52016,"source":{"system":"sec-edgar","filing":"0000905148-24-002363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514824002363/form4.xml","form_type":"4"}},{"id":1424837,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-23T22:18:08.000Z","date":"2024-08-21","kind":"purchase","planned":false,"acquired":true,"shares":1200,"price":1.6988,"value":2038.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.685 through $1.70, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth."}],"balance_after":47922,"source":{"system":"sec-edgar","filing":"0000905148-24-002340","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514824002340/form4.xml","form_type":"4"}},{"id":1719676,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-05","kind":"exercise","planned":false,"acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719675,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-07","kind":"sale","planned":false,"acquired":false,"shares":4550,"price":2.239,"value":10187.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":62565,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719674,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-06","kind":"sale","planned":false,"acquired":false,"shares":14500,"price":2.3101,"value":33496.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth."}],"balance_after":67115,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1719673,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-07T21:51:56.000Z","date":"2023-12-05","kind":"exercise","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":81615,"source":{"system":"sec-edgar","filing":"0001209191-23-057725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123057725/doc4.xml","form_type":"4"}},{"id":1738508,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks."}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share (\"Common Stock\")","published_at":"2023-11-17T14:27:23.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":877192,"price":2.28,"value":1999997.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Stock was purchased in connection with a Subscription Agreement entered into as of May 1, 2023 between the Issuer and Rubric Capital, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":2946908,"source":{"system":"sec-edgar","filing":"0001104659-23-119331","document":"tm2330971-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465923119331/tm2330971-1_4seq1.xml","form_type":"4"}},{"id":1801414,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":110391,"kind":"person","name":"ZIEGLER JOSEPH","position":1,"cik":"0001979286","reported_name":"ZIEGLER JOSEPH","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-21T20:22:58.000Z","date":"2023-08-17","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock of the Issuer are to be acquired upon the vesting of restricted stock units (\"RSUs\") granted to the Reporting Person. The RSUs shall fully vest on the earlier of August 17, 2024 or a Change in Control of the Issuer (as defined in the Issuer's 2019 Stock Incentive Plan)."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-23-046702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123046702/doc4.xml","form_type":"4"}},{"id":1827476,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":29039,"kind":"person","name":"Thompson Tommy G","position":1,"cik":"0001324863","reported_name":"Thompson Tommy G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-19T21:29:57.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-23-042767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123042767/doc4.xml","form_type":"4"}},{"id":1827475,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-19T21:28:26.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-23-042765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123042765/doc4.xml","form_type":"4"}},{"id":1827474,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73615,"kind":"person","name":"Collins Cooper C.","position":1,"cik":"0001485508","reported_name":"Collins Cooper C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-19T21:27:06.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-23-042763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123042763/doc4.xml","form_type":"4"}},{"id":1842446,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock, par value $0.001 per share (\"Common Stock\")","published_at":"2023-06-29T21:21:32.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":312525,"price":3.6797,"value":1149998.2425,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Common Stock was purchased in connection with a Subscription Agreement entered into as of May 1, 2023 between the Issuer and Rubric Capital, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":2069716,"source":{"system":"sec-edgar","filing":"0001104659-23-076387","document":"tm2320269-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465923076387/tm2320269-1_4seq1.xml","form_type":"4"}},{"id":1905374,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905373,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905372,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"sale","planned":false,"acquired":false,"shares":692,"price":3.6381,"value":2517.5652,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":11615,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905371,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date.  The restricted stock units settled on April 26, 2023."}],"balance_after":12307,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1905370,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:38:07.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The beneficially owned shares have been adjusted as the restricted stock units previously reported as settled on April 12, 2023 were not settled on that date.  The restricted stock units settled on April 26, 2023."}],"balance_after":14041,"source":{"system":"sec-edgar","filing":"0001209191-23-027361","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123027361/doc4a.xml","form_type":"4/A","original_submission_date":"2023-04-14"}},{"id":1920112,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023.  One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021.  Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The vested performance stock units (PSUs) represent PSUs deemed by the compensation committee to be vested at target due to the change in the issuer's business model. The remaining PSUs vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023.  One quarter of the initial PSUs were forfeited based on the failure of the issuer to achieve certain EBITDA milestones for the year ended December 31, 2021.  Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920111,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920110,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920109,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Units","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":3030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance stock units (PSUs) vested upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs would have been forfeited. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3030},"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920108,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"sale","planned":false,"acquired":false,"shares":1170,"price":3.6543,"value":4275.531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $3.63 through $3.71, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":12307,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920107,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13477,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920106,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11743,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920105,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10009,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920104,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:20:38.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":3030,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8999,"source":{"system":"sec-edgar","filing":"0001209191-23-024388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024388/doc4.xml","form_type":"4"}},{"id":1920103,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-04-14T23:17:22.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-024386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024386/doc4.xml","form_type":"4"}},{"id":1920102,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-04-14T23:17:22.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":61853,"source":{"system":"sec-edgar","filing":"0001209191-23-024386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123024386/doc4.xml","form_type":"4"}},{"id":1998217,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-23T22:16:08.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on June 30, 2023."}],"balance_after":70000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-23-012287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123012287/doc4.xml","form_type":"4"}},{"id":1998221,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-23T22:11:20.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in full on March 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-012271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123012271/doc4.xml","form_type":"4"}},{"id":2002563,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See remarks"}}],"security":"Series A Preferred Stock, par value $0.001 per share","published_at":"2023-02-22T21:32:31.000Z","date":"2022-12-30","kind":"disposition_to_issuer","acquired":false,"shares":29000,"price":1333,"value":38657000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock was mandatorily redeemed by the Issuer pursuant to Section 6(b) of the Certificate of Designation, Preferences and Rights of Series A Preferred Stock, establishing the powers designations, preferences and privileges, and the qualifications, limitations or restrictions of the Series A Preferred Stock (the \"Series A Preferred Stock COD\") at a redemption price of $1,333 per share. A copy of Series A Preferred Stock COD was filed by the Issuer as Exhibit 3.1 of the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 1, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-024323","document":"tm237613-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465923024323/tm237613-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-01-03"}},{"id":2021962,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-02-13T22:23:55.000Z","date":"2022-12-08","kind":"gift","acquired":false,"shares":716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a charitable donation."}],"balance_after":5969,"source":{"system":"sec-edgar","filing":"0001209191-23-008817","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123008817/doc5.xml","form_type":"5"}},{"id":2043315,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1140},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043314,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043313,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Performance Stock Units","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043312,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":49,"price":5.09,"value":249.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":11853,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043311,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"sale","acquired":false,"shares":1648,"price":5.0796,"value":8371.1808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":11902,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043310,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":13550,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043309,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":12410,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2043308,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-30T23:40:57.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs)."}],"balance_after":10010,"source":{"system":"sec-edgar","filing":"0001209191-23-005554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123005554/doc4.xml","form_type":"4"}},{"id":2047138,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2400},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047137,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":519},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047136,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":1066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1066},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047135,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023.  Vesting was accelerated in connection with the termination of the reporting person's employment agreement without \"Good Cause\"."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047134,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":7,"price":5.3101,"value":37.1707,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."}],"balance_after":7610,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047133,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":1302,"price":5.3383,"value":6950.4666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":7617,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047132,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":2400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":8919,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047131,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6519,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047130,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":1066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2047129,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin. Fin. and Acctg. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:50:27.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4934,"source":{"system":"sec-edgar","filing":"0001209191-23-004871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123004871/doc4.xml","form_type":"4"}},{"id":2073951,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock, par value $0.001 per share","published_at":"2023-01-03T20:33:55.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":29000,"price":1333,"value":38657000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-000311","document":"tm231445-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465923000311/tm231445-1_4seq1.xml","form_type":"4"}},{"id":2090688,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share (\"Common Stock\")","published_at":"2022-12-12T16:14:36.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":14825,"price":6.09,"value":90284.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.15, inclusive.  The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.  Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":1757191,"source":{"system":"sec-edgar","filing":"0001104659-22-126117","document":"tm2232455-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465922126117/tm2232455-1_4seq1.xml","form_type":"4"}},{"id":2091819,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":121758,"kind":"person","name":"Bernick Brian","position":1,"cik":"0001532233","reported_name":"Bernick Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:41:23.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":3167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022."}],"balance_after":10517,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3167},"source":{"system":"sec-edgar","filing":"0001209191-22-060588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060588/doc4.xml","form_type":"4"}},{"id":2091818,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":121758,"kind":"person","name":"Bernick Brian","position":1,"cik":"0001532233","reported_name":"Bernick Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:41:23.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":320,"price":6.3121,"value":2019.872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"}],"balance_after":3872,"source":{"system":"sec-edgar","filing":"0001209191-22-060588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060588/doc4.xml","form_type":"4"}},{"id":2091817,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":121758,"kind":"person","name":"Bernick Brian","position":1,"cik":"0001532233","reported_name":"Bernick Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:41:23.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":935,"price":4.9215,"value":4601.6025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":4192,"source":{"system":"sec-edgar","filing":"0001209191-22-060588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060588/doc4.xml","form_type":"4"}},{"id":2091816,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":121758,"kind":"person","name":"Bernick Brian","position":1,"cik":"0001532233","reported_name":"Bernick Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:41:23.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":3167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":5127,"source":{"system":"sec-edgar","filing":"0001209191-22-060588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060588/doc4.xml","form_type":"4"}},{"id":2091815,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":770,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":388},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091814,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":2311,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1156},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091813,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023."}],"balance_after":1010,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091812,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":1048,"price":4.9475,"value":5184.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.66 through $5.41, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":6685,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091811,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":7733,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091810,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":7345,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091809,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73613,"kind":"person","name":"Walker Marlan D","position":1,"cik":"0001820187","reported_name":"Walker Marlan D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:31.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":6189,"source":{"system":"sec-edgar","filing":"0001209191-22-060587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060587/doc4.xml","form_type":"4"}},{"id":2091808,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer."}],"balance_after":3466,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2091807,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":440,"price":4.9215,"value":2165.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations"}],"balance_after":1294,"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2091806,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":18713,"kind":"person","name":"Glickman Mark A","position":1,"cik":"0001441461","reported_name":"Glickman Mark A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Co-Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-10T00:38:08.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":1734,"source":{"system":"sec-edgar","filing":"0001209191-22-060586","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060586/doc4.xml","form_type":"4"}},{"id":2091805,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024."}],"balance_after":519,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":262},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091804,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":1066,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":534},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091803,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023."}],"balance_after":380,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091802,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Restricted Stock Units","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091801,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"sale","acquired":false,"shares":910,"price":4.775,"value":4345.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":4554,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091800,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":5464,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091799,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":5202,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091798,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4668,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091797,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":114471,"kind":"person","name":"Donegan Michael C","position":1,"cik":"0001627810","reported_name":"Donegan Michael C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO/CAO/VP of Finance"}}],"security":"Common Stock","published_at":"2022-12-10T00:37:34.000Z","date":"2022-12-06","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of issuer common stock upon settlement.  On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs)."}],"balance_after":4288,"source":{"system":"sec-edgar","filing":"0001209191-22-060585","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060585/doc4.xml","form_type":"4"}},{"id":2091796,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-09T15:58:43.000Z","date":"2022-12-08","kind":"purchase","acquired":true,"shares":300,"price":5.83,"value":1749.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.80 to $5.85 inclusive.  The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.  Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":1742366,"source":{"system":"sec-edgar","filing":"0001104659-22-125712","document":"tm2232348-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465922125712/tm2232348-1_4seq1.xml","form_type":"4"}},{"id":2091795,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":74187,"kind":"organization","name":"Rubric Capital Management LP","position":1,"cik":"0001687509","reported_name":"Rubric Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74188,"kind":"person","name":"Rosen David Efraim","position":2,"cik":"0001898677","reported_name":"Rosen David Efraim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share (\"Common Stock\")","published_at":"2022-12-09T15:58:43.000Z","date":"2022-12-07","kind":"purchase","acquired":true,"shares":20113,"price":5.6625,"value":113889.8625,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $5.14 to $5.75, inclusive.  The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is filed by Rubric Capital Management LP (\"Rubric Capital\") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the \"Rubric Vehicles\"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.  Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":1742066,"source":{"system":"sec-edgar","filing":"0001104659-22-125712","document":"tm2232348-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000110465922125712/tm2232348-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2022-12-09T15:58:43.000000Z,2091795"}